InfuSystem Holdings, Inc. $INFU Shares Sold by AWM Investment Company Inc.

Key Points

• AWM Investment Company Inc. reduced its stake in InfuSystem Holdings by 12.8%, now holding 1,626,280 shares valued at approximately $8.75 million.
• Several major institutional investors have increased their holdings, with BNP Paribas Financial Markets growing its stake by 67.9% in the last quarter.
• Analysts maintain a consensus rating of "Strong Buy" for InfuSystem, with an average price target of $12.50, despite some brokerages adjusting their ratings.

AWM Investment Company Inc. cut its stake in InfuSystem Holdings, Inc. (NYSE:INFU - Free Report) by 12.8% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,626,280 shares of the company's stock after selling 238,935 shares during the quarter. AWM Investment Company Inc. owned 7.74% of InfuSystem worth $8,749,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BNP Paribas Financial Markets boosted its holdings in shares of InfuSystem by 67.9% in the fourth quarter. BNP Paribas Financial Markets now owns 6,844 shares of the company's stock worth $58,000 after buying an additional 2,768 shares during the last quarter. Jump Financial LLC bought a new stake in shares of InfuSystem in the 1st quarter worth about $58,000. Wells Fargo & Company MN increased its holdings in shares of InfuSystem by 51.7% in the 4th quarter. Wells Fargo & Company MN now owns 9,286 shares of the company's stock worth $78,000 after buying an additional 3,165 shares during the last quarter. Virtu Financial LLC bought a new stake in shares of InfuSystem in the 1st quarter worth about $86,000. Finally, MetLife Investment Management LLC bought a new position in InfuSystem during the fourth quarter valued at $110,000. Hedge funds and other institutional investors own 71.13% of the company's stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on INFU. Wall Street Zen cut shares of InfuSystem from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, May 14th. Roth Capital assumed coverage on shares of InfuSystem in a report on Tuesday, July 22nd. They set a "buy" rating and a $12.00 target price on the stock. Three equities research analysts have rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, InfuSystem currently has a consensus rating of "Strong Buy" and a consensus target price of $12.50.

Insider Activity at InfuSystem

In other news, Director Scott Shuda sold 5,752 shares of the firm's stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $9.67, for a total transaction of $55,621.84. Following the sale, the director owned 94,000 shares of the company's stock, valued at $908,980. This trade represents a 5.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 11.40% of the stock is owned by insiders.

InfuSystem Stock Performance

Shares of INFU stock traded down $0.47 during trading hours on Friday, hitting $10.16. The company's stock had a trading volume of 225,946 shares, compared to its average volume of 177,809. The company has a 50 day moving average of $7.62 and a 200 day moving average of $6.41. The stock has a market cap of $207.53 million, a PE ratio of 169.36 and a beta of 1.82. The company has a current ratio of 1.98, a quick ratio of 1.59 and a debt-to-equity ratio of 0.50. InfuSystem Holdings, Inc. has a 12-month low of $4.61 and a 12-month high of $11.04.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.